SOBI 002

Drug Profile

SOBI 002

Alternative Names: SOBI-002

Latest Information Update: 30 Sep 2015

Price : $50

At a glance

  • Originator Swedish Orphan Biovitrum
  • Class Proteins
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Inflammation

Most Recent Events

  • 16 Jul 2015 Discontinued - Phase-I for Inflammation (In volunteers) in United Kingdom (SC)
  • 16 Jul 2015 Discontinued - Phase-I for Inflammation (In volunteers) in United Kingdom (IV)
  • 16 Jul 2015 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top